AstraZeneca's Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with chronic kidney disease, extending its lead over rival drugs in the class.

The approval gives Boehringer and Lilly an opportunity to regain ascendency in the SGLT2 market after a prolonged period of sustained growth for AZ's Forxiga (dapagliflozin) – known as Farxiga ...

AstraZeneca is investing in the broadest and ... For example, by building on the success of Forxiga (dapagliflozin), the first SGLT2 inhibitor to demonstrate a mortality benefit in chronic kidney ...